[1] |
General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
|
[2] |
Chinese Journal of Hepatology; Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma(2020 edition)[J]. J Clin Hepatol, 2020, 36( 3): 514- 518. DOI: 10.3969/j.issn.1001-5256.2020.003.007.
《中华肝脏病杂志》编辑委员会, 中华医学会肝病学分会肝癌学组. 肝细胞癌癌前病变的诊断和治疗多学科专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36( 3): 514- 518. DOI: 10.3969/j.issn.1001-5256.2020.003.007.
|
[3] |
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
|
[4] |
SONG B, YAN FH. Chinese imaging medicine-hepatobiliary pancreatic spleen volume[M]. 3rd ed. Beijing: People’s Medical Publishing House, 2019: 78- 80.
宋彬, 严福华. 中华影像医学·肝胆胰脾卷[M]. 3版. 北京: 人民卫生出版社, 2019: 78- 80.
|
[5] |
FAN XL, LING Q, FANG Z, et al. Clinical value of MRI in the diagnosis of small hepatocellular carcinoma with disodium gadolinium sephate in the context of liver cirrhosis[J]. Imag Sci Photochem, 2020, 38( 6): 1038- 1042. DOI: 10.7517/issn.1674-0475.200410.
范晓黎, 凌茜, 方正, 等. MRI在肝硬化背景下诊断小肝癌中联用钆塞酸二钠的临床价值分析[J]. 影像科学与光化学, 2020, 38( 6): 1038- 1042. DOI: 10.7517/issn.1674-0475.200410.
|
[6] |
WANG Q, SHENG ZX. Constitution theory of traditional Chinese medicine[M]. Nanjing: Phoenix Science Press, 1982: 15.
王琦, 盛增秀. 中医体质学说[M]. 南京: 江苏科学技术出版社, 1982: 15.
|
[7] |
TENG X, JIN T, LIU Y, et al. Research progress in the relationship between genetic mechanisms of vestibular migraine and constitution of traditional Chinese medicine[J]. J Changchun Univ Chin Med, 2023, 39( 1): 108- 112. DOI: 10.13463/j.cnki.cczyy.2023.01.024.
滕鑫, 荆涛, 刘寅, 等. 前庭性偏头痛遗传学机制与中医体质关系的研究进展[J]. 长春中医药大学学报, 2023, 39( 1): 108- 112. DOI: 10.13463/j.cnki.cczyy.2023.01.024.
|
[8] |
YAO XX, HAO YK, XIAO Z, et al. Distribution of traditional Chinese medicine syndrome types and elements in liver cirrhosis patients with dysplastic nodules: An analysis of 138 cases[J]. J Clin Hepatol, 2023, 39( 2): 352- 358. DOI: 10.3969/j.issn.1001-5256.2023.02.015.
姚肖肖, 郝尧坤, 肖准, 等. 138例肝硬化不典型增生结节患者中医证型证素分布分析[J]. 临床肝胆病杂志, 2023, 39( 2): 352- 358. DOI: 10.3969/j.issn.1001-5256.2023.02.015.
|
[9] |
HUANG Q, LI JT, ZHANG HB, et al. Li Jingtao’s experience in diagnosis and treatment of precancerous lesions of liver cancer[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30( 3): 246- 248. DOI: 10.3969/j.issn.1005-0264.2020.03.018.
黄倩, 李京涛, 张海博, 等. 李京涛诊治肝癌癌前病变经验探析[J]. 中西医结合肝病杂志, 2020, 30( 3): 246- 248. DOI: 10.3969/j.issn.1005-0264.2020.03.018.
|
[10] |
HUANG JJ, CHEN SL, PAN Z, et al. Treatment of precancerous lesions of liver cancer with toxic turbidity and blood stasis[J]. Chin J Integr Tradit West Med Liver Dis, 2014, 24( 1): 59- 60. DOI: 10.3969/j.issn.1005-0264.2013.06.018.
黄晶晶, 陈松林, 潘哲, 等. 毒浊瘀论治肝癌癌前病变[J]. 中西医结合肝病杂志, 2014, 24( 1): 59- 60. DOI: 10.3969/j.issn.1005-0264.2013.06.018.
|
[11] |
GONG PQ, CHI XL, JIANG YY. Chi xiaoling’s experience on diagnosis and treatment of liver cirrhosis[J]. Chin Arch Tradit Chin Med, 2018, 36( 12): 2996- 2999. DOI: 10.13193/j.issn.1673-7717.2018.12.046.
公培强, 池晓玲, 蒋元烨. 池晓玲教授对肝硬化的证治经验[J]. 中华中医药学刊, 2018, 36( 12): 2996- 2999. DOI: 10.13193/j.issn.1673-7717.2018.12.046.
|
[12] |
XIAO HM, LI S, XIE YB, et al. Discussion on the theory and application of soothing liver and strengthening spleen in the treatment of chronic liver disease[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 7): 651- 653. DOI: 10.3969/j.issn.1005-0264.2021.07.020.
萧焕明, 黎胜, 谢玉宝, 等. 疏肝健脾法治疗慢性肝病的理论与应用探讨[J]. 中西医结合肝病杂志, 2021, 31( 7): 651- 653. DOI: 10.3969/j.issn.1005-0264.2021.07.020.
|
[13] |
ZHOU L. Physical analysis of patients with family history of hepatitis B cirrhosis[D]. Shenyang: Liaoning University of Traditional Chinese Medicine, 2013.
周浪. 具有乙肝肝硬化家族史的患者的体质分析[D]. 沈阳: 辽宁中医药大学, 2013.
|
[14] |
NG CH, CHAN SW, LEE WK, et al. Hepatocarcinogenesis of regenerative and dysplastic nodules in Chinese patients[J]. Hong Kong Med J, 2011, 17( 1): 11- 19.
|
[15] |
CHO HJ, KIM B, LEE JD, et al. Development of risk prediction model for hepatocellular carcinoma progression of indeterminate nodules in hepatitis B virus-related cirrhotic liver[J]. Am J Gastroenterol, 2017, 112( 3): 460- 470. DOI: 10.1038/ajg.2016.480.
|
[16] |
PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016, 64( 4): 800- 806. DOI: 10.1016/j.jhep.2015.11.035.
|
[17] |
YU JH, SUH YJ, JIN YJ, et al. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir[J]. Eur J Gastroenterol Hepatol, 2019, 31( 7): 865- 872. DOI: 10.1097/MEG.0000000000001357.
|
[18] |
WANG Y, ZHOU YT, CHEN RX, et al. The prognostic value of total bile acid for patients with hepatocellular carcinoma[J]. Chin J Clin Med, 2019, 26( 4): 594- 597. DOI: 10.12025/j.issn.1008-6358.2019.20190519.
王妍, 周颖婷, 陈荣新, 等. 血清总胆汁酸水平对肝细胞肝癌患者预后的影响[J]. 中国临床医学, 2019, 26( 4): 594- 597. DOI: 10.12025/j.issn.1008-6358.2019.20190519.
|
[19] |
CHIANG HH, LEE CM, HU TH, et al. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir[J]. Liver Int, 2018, 38( 11): 1997- 2005. DOI: 10.1111/liv.13889.
|